Skip to main content
$11.10 -$0.03 (-0.3%)

04:00 PM EST on 12/07/22

Oyster Point Pharma (NASDAQ:OYST)

CAPS Rating: No stars

Current Price $11.10 Mkt Cap $301.3M
Open $11.12 P/E Ratio 0.00
Prev. Close $11.10 Div. (Yield) $0.00 (0.0%)
Daily Range $11.10 - $11.20 Volume 122,575
52-Wk Range $3.46 - $19.98 Avg. Daily Vol. 436,930


How do you think NASDAQ:OYST will perform against the market?

Add Stock to CAPS Watchlist

All Players

2 Outperform
0 Underperform

All-Star Players

0 Outperform
0 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:OYST Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!


Recent Community Commentary

Read the most recent pitches from players about OYST.


Member Avatar odocoileus (54.89) Submitted: 8/1/2020 12:11:28 PM : Outperform Start Price: $23.65 NASDAQ:OYST Score: -72.81

OYST is wading into a competitive market against some big players. That always gives me pause, as I've been burned in this situation before. However, they only need $100-200M in sales to support their current market cap. In a 2.5B North American market and a 4.5B worldwide market for dry eye disease, there's probably room to run. Especially since they have a unique delivery method. It remains to be seen whether folks would rather inhale a drug than put drops in their eyes. The long process of manufacturing, marketing, and gaining insurance coverage is a long one, and I don't know how effective management will be in this arena. But they have passed PIII trials with flying colors, and we should see a bump on FDA submission, approval, and various announcements their PR machine should pump out as they progress through marketing. The real meat will be in sales, which should start mid 2021, so we won't know how that's going until the end of 2021 or into 2022. One could wait to see how sales develop, but it's rare to find a company that has passed PIII trials in a significant market with a low market cap.


Find the members with the highest scoring picks in OYST.

Score Leader


mrbill6 (60.78) Score: +85.04

The Score Leader is the player with the highest score across all their picks in OYST.

Member Name Member
Call Time
Score Commentary
mrbill6 60.78 7/25/2022 Outperform 5Y $6.02 +84.39% -0.65% +85.04 0 Comment
odocoileus 54.89 8/3/2020 Outperform 5Y $23.65 -53.07% +19.75% -72.81 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for OYST.